Chemoreflex Sensitivity in HFpEF
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: chemoreflex evaluation.
- Who it may be relevant to
- Registry conditions: Heart Failure With Preserved Ejection Fraction. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Italy
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Chemoreflex Sensitivity in Heart Failure With Preserved Ejection Fraction
Overview
Patients with heart failure and a preserved left ventricular ejection fraction (HFpEF) almost invariably complain of exertional breathlessness. Abnormal cardiac hemodynamics with pulmonary congestion are believed to trigger dyspnea in this patients. However, some patients may complain of exertional breathlessness which seems to be out of proportion as compared with hemodynamic abnormalities. Chemoreflex sensitivity accounts for the ventilatory responses to a variety of chemical stimuli, including carbon dioxide produced by the organism during exercise. Chemoreflex sensitivity can be augmented in heart failure with reduced left ventricular ejection fraction, and an increased chemoreflex sensitivity has been linked to symptoms, neurohumoral activation, breathing disturbances, and adverse prognosis. However, the clinical correlates and implications of chemoreflex sensitivity in HFpEF have not been accurately studied. We aim to characterize chemoreflex sensitivity in patients with a diagnosis of HFpEF, and to correlate chemoreflex sensitivity with clinical and hemodynamic characteristics.
Interventions
- Diagnostic test chemoreflex evaluation
the ventilatory response to carbon dioxide and hypoxia will be assessed in study participants
Primary outcome measures
- difference in chemoreflex sensitivity between HFpEF and healthy controls [Time frame: 5 years]
Eligibility criteria
Inclusion criteria
- diagnosis of symptomatic HFpEF (group 1)
- diagnosis of asymptomatic left ventricular diastolic dysfunction with echocardiographic signs of PH (group 2)
- healthy volunteers (group 3)
Exclusion criteria
- breastfeeding or childbearing
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
Italy · 1 center
- Ospedale San Luca IRCCS Istituto Auxologico Italiano — Milan
Identifiers
NCT: NCT06309537 · 09C830